Dow Inc.
DOW
$28.75
-3.65%
Dow Inc. is a diversified global chemicals producer, formed in 2019 from the DowDuPont merger, and a leading manufacturer of polyethylene, ethylene oxide, and silicone rubber for consumer and industrial markets. As one of the world's largest chemical companies, it holds a dominant position in commodity and specialty chemicals, with a broad portfolio spanning packaging, infrastructure, and coatings. The current investor narrative centers on the impact of Middle East supply chain disruptions, particularly the Strait of Hormuz closure, which has pressured margins and caused a revenue miss in Q1 2026, though cost-saving initiatives and a reopening of the strait offer a potential recovery path.…
DOW
Dow Inc.
$28.75
Related headlines
Investment Opinion: Should I buy DOW Today?
Rating: Hold. Dow is a deeply cyclical chemical stock trading at a distressed valuation, but the lack of near-term earnings visibility and ongoing cash burn warrant caution. The analyst consensus is Buy with an average target of $36.25, implying 21.5% upside, but the fundamental deterioration suggests the stock is a value trap until a clear recovery catalyst emerges.
Supporting Evidence: Dow's trailing PS of 0.42x is a 60% discount to the typical chemical industry PS of 1.0-1.5x, indicating deep value. However, revenue is declining 6.1% YoY, and the company has negative net income of -$445 million in Q1 2026. Gross margin has halved to 6.5%, and free cash flow is negative -$1.395 billion TTM. The dividend yield of 8.96% provides some downside protection, but the payout ratio of -56.8% (based on negative earnings) suggests the dividend is not sustainable without a recovery. The forward PE of 16.1x (based on estimated EPS of $2.28) is not cheap if earnings fail to materialize.
Risks & Conditions: The Hold rating would upgrade to Buy if the company returns to positive free cash flow and gross margins recover above 10%, or if the stock falls below $25, offering a wider margin of safety. It would downgrade to Sell if revenue declines accelerate beyond -10% YoY or if the dividend is cut. The biggest risks are a prolonged chemical downturn, failure of cost-saving initiatives, and a resurgence of geopolitical disruptions. Overall, Dow appears undervalued on a historical and peer basis, but the valuation is justified by the poor fundamental outlook, making it a speculative hold for risk-tolerant investors.
Sign up to view all
DOW 12-Month Price Forecast
Dow's outlook is highly uncertain, balanced between a deep value recovery and a prolonged downturn. The base case of a gradual recovery to $36.25 is most probable (50%), but the bear case (25%) and bull case (25%) are equally likely, reflecting the binary nature of the chemical cycle. The key swing factor is the pace of margin recovery: if gross margins can return to 10%+ by year-end, the stock could rally; if they stay below 8%, further downside is likely. The neutral stance reflects the lack of clear catalysts and the risk of continued losses. An upgrade to bullish would require evidence of sustainable profitability, while a downgrade to bearish would follow a dividend cut or renewed geopolitical crisis.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dow Inc.'s 12-month outlook, with a consensus price target around $35.69 and implied upside of +24.1% versus the current price.
Average Target
$35.69
0 analysts
Implied Upside
+24.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$29 - $48
Analyst target range
Dow is covered by 16 analysts, with a consensus recommendation of 'Buy' (mean rating 2.39 on a 1-5 scale where 1 is Strong Buy). The average target price is $36.25, implying 21.5% upside from the current price of $29.84. The distribution includes 8 Buy, 5 Hold, and 3 Sell ratings, indicating a moderately bullish consensus. The target range spans from a low of $29.00 to a high of $48.00. The high target of $48.00 assumes a significant recovery in chemical margins and a resolution of geopolitical disruptions, while the low target of $29.00 suggests continued weakness or a further decline. Recent ratings actions show mixed signals: RBC Capital downgraded from Outperform to Sector Perform on July 1, while Argus upgraded from Hold to Buy in May. The wide spread between low and high targets ($19) reflects high uncertainty around the timing and magnitude of a recovery, typical for cyclical chemical stocks.
Bulls vs Bears: DOW Investment Factors
Dow presents a classic cyclical value trap versus recovery play. The bull case rests on deep valuation (0.42x PS), a consensus Buy rating with 21.5% upside, and a potential catalyst from the Strait of Hormuz reopening that could restore margins. However, the bear case is equally compelling: negative net income, declining revenue, collapsing gross margins, and cash burn suggest the company is in a severe downturn with no clear near-term recovery. The single most important tension is whether the chemical cycle has bottomed and will recover, or whether structural headwinds (overcapacity, weak demand) will prolong losses. Currently, the bearish evidence from fundamentals outweighs the valuation argument, making the stock a high-risk speculative buy for patient investors only.
Bullish
- Deep Value at 0.42x PS: Dow trades at a trailing PS ratio of 0.42x, near its historical low and well below the typical chemical industry range of 1.0-1.5x. This implies the market is pricing in a prolonged downturn, offering a potential value entry if earnings recover.
- Analyst Consensus Buy with 21.5% Upside: 16 analysts rate Dow a Buy on average, with a mean target of $36.25, implying 21.5% upside from the current $29.84. The high target of $48.00 suggests significant recovery potential if geopolitical disruptions resolve.
- Strait of Hormuz Reopening Catalyst: The reopening of the Strait of Hormuz in April 2026 removes a major supply chain disruption that had pressured margins. This de-escalation could restore petrochemical pricing and volumes, driving a recovery in Dow's earnings.
- Dividend Yield of 8.96% Provides Floor: Dow's quarterly dividend of $0.35 per share yields 8.96%, supported by a 114-year payment streak. This high yield offers a substantial income return and may attract value-oriented investors, limiting downside.
Bearish
- Negative Net Income and Cash Burn: Dow reported a net loss of -$445 million in Q1 2026 and trailing twelve-month free cash flow of -$1.395 billion. The company is burning cash, with negative ROE of -16.4%, indicating shareholder value destruction.
- Revenue Declining 6.1% YoY: Q1 2026 revenue of $9.794 billion fell 6.1% year-over-year, with broad-based weakness across all segments. The trailing twelve-month revenue trend shows a steady decline from $10.915 billion in Q2 2024, signaling persistent demand challenges.
- Gross Margin Collapsed to 6.5%: Gross margin plummeted from 11.4% in Q2 2024 to just 6.5% in Q1 2026, reflecting severe pricing pressure and high input costs. Operating margin was -0.3%, meaning the company barely covers operating expenses.
- High Debt-to-Equity of 1.22x: With debt-to-equity at 1.22x and negative free cash flow, Dow's elevated leverage increases financial risk. Interest expense of $219 million per quarter consumes a significant portion of operating cash flow, limiting financial flexibility.
DOW Technical Analysis
Dow's stock is in a clear downtrend from its 52-week high of $42.74, with the current price of $29.84 representing 69.8% of the 52-week range. The 1-year price change of +19.0% masks a significant decline from the highs, as the stock has fallen 30.2% from its peak, indicating a bearish reversal after a strong prior year. The price sits near the lower end of the range, suggesting the stock is oversold but also reflecting persistent selling pressure and a lack of momentum. Short-term momentum is mixed: the 1-month change of +1.6% shows a slight recovery, but the 3-month change of -22.8% reveals a sharp decline, diverging sharply from the positive 1-year trend. This divergence suggests the recent uptick may be a dead-cat bounce or mean-reversion within a broader downtrend, rather than a sustainable reversal. The RSI is not provided, but the volume of 10.4 million shares on the latest day is elevated, indicating active trading. Key support is at the 52-week low of $20.40, while resistance is at the 52-week high of $42.74. A break below $20.40 would signal further downside risk, while a move above $42.74 would indicate a trend reversal. Beta is not provided, but the stock's volatility is evident from its 35.5% maximum drawdown over the period, suggesting higher risk than the market.
Beta
0.43
0.43x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$20-$43
Price range past year
Annual Return
+12.7%
Cumulative gain past year
| Period | DOW Return | S&P 500 |
|---|---|---|
| 1m | -1.0% | +1.4% |
| 3m | -24.4% | +3.9% |
| 6m | +3.5% | +6.3% |
| 1y | +12.7% | +16.0% |
| ytd | +18.5% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOW Fundamental Analysis
Revenue has been declining, with Q1 2026 revenue of $9.794 billion down 6.1% year-over-year, and the trailing twelve-month revenue trend shows a deceleration from $10.915 billion in Q2 2024 to $9.794 billion in Q1 2026. The Packaging & Specialty Plastics segment contributed $4.919 billion, while Industrial Intermediates & Infrastructure and Performance Materials & Coatings added $2.626 billion and $2.080 billion, respectively, indicating broad-based weakness. The revenue decline reflects lower volumes and pricing power amid a global chemical downturn and supply chain disruptions. Profitability is under severe pressure: net income was -$445 million in Q1 2026, with a gross margin of only 6.5%, down from 11.4% in Q2 2024. The company has posted negative net income in four of the last five quarters, with a trailing twelve-month net loss of -$2.273 billion. Operating margin was -0.3% in Q1 2026, indicating the company is barely covering operating costs, and the negative net margin of -4.5% highlights the lack of profitability. The balance sheet shows a debt-to-equity ratio of 1.22, which is elevated but manageable, and a current ratio of 1.97, indicating adequate liquidity. However, free cash flow was negative -$1.395 billion on a trailing twelve-month basis, and the company generated only $1.124 billion in operating cash flow in Q1 2026, which barely covers capital expenditures of $503 million. ROE is -16.4%, reflecting shareholder value destruction, and the company relies on debt financing to fund operations, increasing financial risk.
Quarterly Revenue
$9.8B
2026-03
Revenue YoY Growth
-6.1%
YoY Comparison
Gross Margin
6.5%
Latest Quarter
Free Cash Flow
$-1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOW Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 0.42x, while the forward PS ratio (based on estimated revenue of $45.4 billion) is approximately 0.37x, implying a slight discount to trailing sales. The gap between trailing and forward PS suggests the market expects revenue to decline further, which aligns with the recent downtrend. Compared to the industry average PS ratio (not provided, but typically for chemicals around 1.0-1.5x), Dow's PS of 0.42x is a significant discount, indicating the market is pricing in a prolonged downturn or structural challenges. The EV/Sales ratio of 0.95x also suggests a discount to enterprise value. Historically, Dow's PS ratio has ranged from 1.6x to 3.8x over the past five years, with the current 0.42x near the bottom of its historical band. This low valuation implies the market is pricing in pessimistic expectations, but it could also represent a value opportunity if the company's earnings recover. The PB ratio of 1.04x is also near historical lows, further supporting the undervaluation thesis.
PE
-6.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Dow's financial health is under severe strain. The company posted a net loss of -$445 million in Q1 2026 and negative free cash flow of -$1.395 billion over the trailing twelve months. Gross margin has collapsed to 6.5% from 11.4% a year earlier, and operating margin is negative at -0.3%. With debt-to-equity of 1.22x, the company's interest expense of $219 million per quarter consumes a large portion of its $1.124 billion in quarterly operating cash flow, leaving little room for error. The negative ROE of -16.4% indicates ongoing shareholder value destruction, and the reliance on debt to fund operations increases vulnerability to further earnings deterioration.
Market & Competitive Risks: Dow's valuation, while low on a PS basis, could compress further if earnings continue to disappoint. The stock's 35.5% maximum drawdown over the period highlights its high volatility and sensitivity to macro factors. The chemical industry faces headwinds from global overcapacity, weak demand in packaging and construction, and geopolitical disruptions. The recent closure of the Strait of Hormuz exacerbated margin pressure, and while it has reopened, the CEO warned that the petrochemical shock could take 275 days to clear. Competitive risks include lower-cost producers in the Middle East and Asia that could capture market share if Dow's cost structure remains uncompetitive.
Worst-Case Scenario: In a prolonged downturn with continued losses and no recovery in chemical margins, Dow's stock could fall to its 52-week low of $20.40, representing a 31.6% decline from the current price of $29.84. This scenario could be triggered by a resurgence of geopolitical tensions, a global recession reducing demand, or a failure of cost-saving initiatives to restore profitability. At $20.40, the PS ratio would compress to approximately 0.29x, reflecting deep distress. Investors could lose up to 31.6% of their investment in this adverse scenario.
FAQ
The primary risks are: 1) Financial risk: negative net income, -$1.395 billion free cash flow, and debt-to-equity of 1.22x could lead to a dividend cut or balance sheet stress. 2) Cyclical risk: chemical margins are at cyclical lows, and a prolonged downturn could push the stock to $20.40, a 31.6% decline. 3) Geopolitical risk: the Strait of Hormuz closure highlighted vulnerability to supply disruptions; any renewed tensions could spike costs. 4) Competitive risk: lower-cost producers in the Middle East and Asia could capture market share. The most severe risk is a dividend cut, which would likely trigger a sharp sell-off and confirm the bear case.
The 12-month forecast is highly uncertain. The base case (50% probability) sees a gradual recovery to the analyst average target of $36.25, implying 21.5% upside, driven by stabilizing demand and cost savings. The bull case (25% probability) targets $48.00 (61% upside) if margins recover quickly and the chemical cycle turns. The bear case (25% probability) sees downside to $20.40 (31.6% decline) if losses persist and the dividend is cut. The most likely scenario is the base case, but the wide range reflects the binary nature of the chemical cycle. Key assumptions include gross margin recovery above 8% and positive free cash flow by H2 2026.
Dow appears undervalued on a historical and peer basis. Its trailing PS ratio of 0.42x is near the bottom of its five-year range of 1.6x to 3.8x and well below the chemical industry average of 1.0-1.5x. The PB ratio of 1.04x is also near historical lows. However, this low valuation reflects the market's expectation of continued losses and a prolonged downturn. The forward PE of 16.1x based on estimated EPS of $2.28 suggests the stock is not cheap if earnings fail to materialize. In summary, Dow is undervalued relative to its history and peers, but the valuation is justified by the poor fundamental outlook, making it a classic value trap risk.
Dow is a high-risk, high-reward opportunity. At $29.84, it trades at a deep discount with a PS ratio of 0.42x, and analysts see 21.5% upside to the average target of $36.25. However, the company is losing money, with a net loss of -$445 million in Q1 2026 and negative free cash flow. The 8.96% dividend yield is attractive but may not be sustainable if losses continue. For risk-tolerant investors with a long-term horizon who believe the chemical cycle will recover, Dow could be a good buy at current levels. For conservative investors seeking stable earnings, it is not suitable. The biggest risk is further downside to the 52-week low of $20.40, a 31.6% decline.
Dow is better suited for long-term, patient investors with a 12-24 month horizon, given its cyclical nature and current distress. Short-term trading is risky due to high volatility (35.5% max drawdown) and uncertainty around earnings catalysts. The stock's beta is not provided, but its price swings correlate strongly with chemical commodity prices and geopolitical events. Long-term investors can benefit from the 8.96% dividend yield while waiting for a cyclical recovery, but must be prepared for potential dividend cuts. A minimum holding period of 18 months is recommended to allow time for the chemical cycle to turn. For short-term traders, the stock offers opportunities around earnings and news events, but the risk of sharp declines is high.